Labor looks to speed up PBS listings amid calls from lobby groups
Health Minister Mark Butler says he is looking at recommendations to speed up medicine approvals amid pressure from lobbyists both within Australia and in the US.
Medicines Australia has repeatedly highlighted that Australia lags behind comparable countries in listing new medicines on the Pharmaceutical Benefits Scheme (PBS) – a list of federally subsidised medicines.
It takes an average of 466 days from when the Therapeutic Goods Administration approves a medicine to when it becomes affordable on the PBS, according to the peak body.
This is much longer than in the UK and Canada, for example.
The lengthy timeline has also angered the Pharmaceutical Research and Manufacturers of America (PhRMA), which has framed the PBS as a 'non-tariff trade barrier' that harms American companies in representations to the Trump administration.
Lengthy PBS listing times is among PhRMA's core criticisms.
Mr Butler said on Thursday he would look at Medicines Australia's recommendations to make the 'approvals system quicker'.
Powerful pharmaceutical lobbyists in the US have accused Australia of 'freeloading' on the high prices paid by American consumers. Picture: Martin Ollman / NewsWire
'We're getting an enormous number of new medicining coming on to the market,' he told the ABC.
'We're living through a turbocharged period of discovery bringing more and more new medicine, so making sure that we can assess them and approve them very quickly to get them into patients as quickly as possible is something I've said is a real priority for us this term.'
Because the PBS compels drugmakers to negotiate prices with the federal government, PhRMA has accused Australia of 'freeloading' on US-funded research and development.
Meanwhile, American consumers pick up the bill, according to the lobby group.
'The medicines industry, understandably, given their interest, want to make prices higher as well, so there will be a bit of a debate about how we do that,' Mr Butler said.
'But I'm very much on the page of getting medicines more quickly into our system, our PBS system.
'It's a terrific system and we're trying to make medicines cheaper at the same time for Australians.'
PhRMA has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies.
Mr Butler has echoed Anthony Albanese and fellow senior government ministers in ruling out any 'compromise' on the system as part of tariff talks.
US President Donald Trump has written to 17 major drugmakers demanding they drop prices in line with other developed economies. Picture: Brendan Smialowski / AFP
For the moment, Donald Trump's concern with the sector appears to be largely focused on bringing down prices in the US rather than punishing allies for having cheaper medicines.
A RAND Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies.
The answer, according to the US President, is to make pharmaceuticals in the US.
In a warning shot to firms, Mr Trump this week threatened to slap tariffs of up to 250 per cent on foreign-made products.
With Australian pharma exports to the US worth more than $2bn in 2024, it would hit producers Down Under hard.
Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous products, such as bandages.
'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC.
'In one year, 1½ years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.'
He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent.
Mr Trump last week wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers and bring them in line with prices overseas.
Originally published as Labor looks to speed up PBS listings amid calls from lobby groups
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
18 minutes ago
- ABC News
What can we learn from New Zealand's experience with potato mop-top virus?
For the first time, potato mop-top virus has been detected in Australia. Spread by a soil-borne fungus vector that can cling to machinery and other materials, it's so far unclear how the disease made it onto a farm in north-west Tasmania. An incident management team has been created to trace and contain the virus, amid concerns for the state's $300 million potato industry. Seven years ago, one of Australia's closest neighbours was dealing with a detection of the same virus. So what can Tasmania learn from the experience across the ditch? Potato mop-top virus was first recorded in a single potato tuber taken from the storage facility of a processing factory in Canterbury, New Zealand in September 2018. Before then, the disease had never been seen in New Zealand. In Tasmania, the virus has only been detected on one farm and risk mitigation measures have been put in place to try and contain it. But in New Zealand, it wasn't clear exactly which paddock the diseased tuber had come from, so a range of sites were tested and it soon became clear the virus was in several paddocks in Canterbury. Iain Kirkwood, an agronomist and biosecurity manager from industry group Potatoes New Zealand, said an international committee of experts was set up to look at response options in New Zealand. "They very quickly came to the conclusion that we cannot eradicate it, because it's a soil-borne organism which causes a powdery scab, and that can stay in the soil for years and years," Dr Kirkwood said. According to the advisory group, eradication had not been achieved in many other international regions where the virus had been recorded either. The New Zealand response moved from "eradication" to "management". Dr Kirkwood said an entire department of the Ministry for Primary Industries looks at tracking and tracing how various incursions get into the country, but, despite a lot of time and money, it couldn't determine how potato mop-top virus arrived in New Zealand. Potato mop-top virus is also found in the United States. Professor Alexander Karasev from the University of Idaho said it might be difficult to trace how the virus entered Tasmania. "In the US, we suspect that the main route of transmission of the virus is with soil … that might be potted for ornamental [plants] which may not even be related to potatoes," Professor Karasev said. Potato mop-top virus can cause significant yield and quality reductions in potatoes. Dr Kirkwood said there hadn't been any reports of yield impacts in New Zealand. He said the virus was discovered in one seed paddock, and that seed line had to be destroyed and the grower compensated. But he said overall, there hadn't been a major impact on New Zealand's potato industry so far. "We're monitoring it through the processors — they report to us if they see mop-top in their lines — and they're recording it every so often," Dr Kirkwood said. "But it's not causing any significant economic impact either on the growers or the processors right now." The international expert advisory group did give New Zealand a warning, though. "We're hopefully monitoring it sufficiently and that it's not going to creep up upon and cause some major issues, but it's one that you do have to pay attention to." Dr Kirkwood said the most important thing New Zealand did was an early survey, testing about 200 lines of potatoes, including seed potatoes, throughout the whole country, to get a good picture of where and how widespread the virus was. "It's very difficult to carry out a response if you're not certain as to where the disease actually is, so I would encourage Tasmania to do some form of survey," he said. Dr Kirkwood also said it would be important for Biosecurity Tasmania to work with the local industry. "The local industry knows the industry better than anyone else — far better than Biosecurity Tasmania does — so I would encourage them to work closely with the growers and the grower organisations."
News.com.au
an hour ago
- News.com.au
Health Check: Pro Medicus banks the profits as customers go the ‘full stack'
Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run The $32 billion market cap ProMedicus (ASX:PME) has drawn the chapter on what co-founder and CEO Dr Sam Hupert dubs 'the most successful year in the company's history by any measure'. The US-focused radiology imaging house today posted revenue of $213 million for the full year to June 30 2025, up 32%. Net earnings surged 39%, to $115 million. While the numbers were pretty much as expected, the shares surged up to 7% on the prospect of further revenue gains from newly-written contracts. The company is also expanding into areas such as cardiology and pathology – the latter of which could be two-thirds the size of the radiology market. "But it's early days." Hupert describes a 'record year of new contract wins, contract renewals and sales of additional modules'. Revenue rose in the three key jurisdictions of the US, Germany and Australia, but North America led the way with a 36% increase. The company derives about 90% of its revenue from the US. During the year, Pro Medicus won $520 million of new contracts. Yep, that's a record. These included a monster $330 million deal with Trinity Health, one of the biggest not-for-profit networks in the US. The company also signed two key renewals, totalling $130 million. Hupert says more customers are going the 'full stack', which means they are availing of the company's image viewing, archiving and workflow tools. Only the beginning? He adds that many of the recently signed contacts will come on stream 'in the next year and beyond', which means 98% of this revenue is yet to be recognised. He cites forward contracted revenue for the next five years at $948 million, up from $624 million a year ago. Despite the growth, Pro Medicus still accounts for only 10% of the US total addressable market. The company still trades on an extravagant price-earnings multiple, which implies that this 10% will become a much bigger number in the near future. 'We don't have a fixed target in mind, our aim is to get as big a percentage market share as possible,' Hupert says. 'Importantly, we do not see any technical or capacity-related reason why we will not continue to increase our market share materially from here.' Hupert says the company's recent $10 million loan facility to lung imager 4D Medical (ASX:4DX) related to the companies AI capabilities. There's the prospect of adding one or morr 4D products to the Pro Medicus stable. "But I wouldn't read more into it than that." Broker RBC says while the result was broadly in line with consensus, the company pleased with its free cash flow generation and upbeat outlook on contracts. RBC has a 'hold' rating on the stock with a 'price target' of $350. Starpharma shares take a run Starpharma (ASX:SPL) CEO Cheryl Maley's prezzo to Bioshares annual summit in Hobart last week appears to have been enough to spark a 50% share run. The contents weren't new, but Maley did outline how management had tweaked the company's strategy over the last year. Maley started in January 2024. Otherwise, Starpharma's June quarterly report showed customer receipts of $2 million, 51% higher than the March quarter. Net cash outflows were $2 million. Starpharma's reason for being is its dendrimer enhanced product (DEP) platform, which has produced the commercialised bacterial vaginosis treatment Vivagel and the germ-busting nasal spray Viraleze. Before you ask, dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss). The company has oncology programs that combine the dendrimer with three existing drugs. They are irinotecan (colorectal cancer), cabazitaxel (prostate cancer and others). Management is attempting to outlicense these assets. Maley says despite considerable interest 'the licensing process has taken longer than anticipated.' She attributes this to factors including "the evolving oncology landscape shifting towards targeted treatment options and the current geo-political environment, which has impacted the biotechnology industry at large". Starpharma ended the quarter with cash of $15.5 million – enough funding for close to two years – with an expected $3.5 million R&D tax rebate yet to come. Starpharma shares today had a well-earned rest, falling around 10%. Rhythm limbers up for raising Rhythm Biosciences (ASX:RHY) shares are on trading halt pending a capital raising announcement, on or before next Monday. It's not a bad time for the company to tap the market, given its shares have gained 75% over the last month. Rhythm is developing Colostat, a blood-based cancer assay which could replace the commonly used 'poo' tests. The company also owns Genetype, a genetic risk assessment testing platform combining clinical, family history and genetic data. Rhythm bought this asset from the administrators of Genetic Technologies. Tetratherix gets a grant Of course, the best form of funding is the free variety and the recently listed Tetratherix (ASX:TTX) has come up trumps in this regard. The wound-care house has been awarded $3.3 million of non-dilutive funding, under the federal Industry Growth Program grant. Tetratherix is commercialising products based on its polymer biomaterials, which offer claimed benefits such as increased flexibility and bioresorbability. The grant will partly fund a $7.4 million project to take its Tetramatrix platform global, including expanding its production facility near Sydney Airport. The funding spans the current financial year and 2026-27. Tetratherix shares have gained a sprightly 40% since listing on June 30, the only local life sciences IPOs year to date. But if you think that's a drought, there been no US biotech IPO for six months. The last one was diseases specialist Aardvark Therapeutics, which listed on the Nasdaq in mid-February.
News.com.au
5 hours ago
- News.com.au
Rise of emotional architecture and wellness in homes
Features once reserved for luxury wellness retreats are becoming more common in Australian homes, with 'emotional architecture' combined with smart technology driving a revolution in design. With a rise of designers embedding wellness into interiors – including sensory lighting, soundscaping, aroma systems and meditation nooks – wellbeing inclusions are becoming more accessible for homeowners. According to Klemich Real Estate managing director Matt Smith, wellness features which were once an expensive optional extra are becoming a part of core building design as people seek to live in spaces that are calm, peaceful and relaxing. Mr Smith said they are seeing technology developing quickly to support better wellness designed apartments such as ambient lighting shifts, music and even scent diffusion. Some key trends being integrated in Australia include nature first design, such as living walls, planters, view corridors, natural materials such as wood, stone, tactile textiles and rooftop or garden access specified to reduce stress and improve cognitive function. Circadian (human-centric) lighting was another feature, mimicking daylight cycles such as blue-enriched daytime or warmer for the evenings to support sleep and mood, moving from high-end to mainstream apartment specs. New technology is also assisting in this rise, such as air and water health integrated as basic infrastructure. This integration has been made possible by integrated heating and more efficient filters that capture at least 99.9 per cent of airborne particles like pollen, smoke and bacteria. Energy recovery ventilation systems also bring in fresh outdoor air while transferring heat and moisture between incoming and outgoing airstreams. This keeps indoor temperature and humidity more stable while improving indoor air quality. Active reduction systems reduce 'volatile organic compounds', such as paints and cleaning agents, minimising headaches, respiratory irritation or long-term health effects. Emotional or experiential architecture also includes the deliberate use of colour, texture, scale and choreography of spaces to evoke safety, delight or calm, such as framed views and quiet contemplative nooks. Neuroaesthetics and 'experiential' design inform layout decisions, evident in flexible and wellness-enabled floorplans, such as apartments designed with dedicated 'wellness corners' with meditation or yoga alcoves, movable partitions for privacy and tech-ready fitness or recovery micro-spaces. These inclusions can also be integrated in shared-spaces and amenities in apartments such as onsite mental and physical wellness including yoga or meditation rooms, infra-red saunas, recovery lounges, small fitness studios, rooftop gardens and edible landscaping. 'Third spaces' such as semi-public co-working and social spaces are additionally designed for connection, which reduce social isolation. Mr Smith said emotional architecture combined with smart tech is making a very positive difference to the way we live. 'Not long ago this was the domain of very high end luxury living, but now it is becoming both accessible and affordable,' he said. Mr Smith said they expect to see colour palettes change too, where once minimalist and muted tones dominated, it is now predicted different hues such as greens and soft blues will be coming through to help bring the outside in.
